Publications by authors named "Tara Lin"

Claim this Profile
D
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.
Daniel Pollyea, Tessa Kerre, Dries Deeren, Yves Beguin, Tara L Lin, Caroline Lonez

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the impact of delayed study startup on accrual in cancer studies.
Isuru Ratnayake, Anh-Tuan Do, Daniel Gajewski, Sam Pepper, Oluwatobiloba Ige, Tara L Lin

Contemp Clin Trials Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.
Daniel T Peters, Deedra Nicolet, Yazan F Madanat, Jesus Gonzalez-Lugo, Alex Ambinder, Tara Lin

Br J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.
Vinod A Pullarkat, Mark Levis, James McCloskey, Gabriel N Mannis, Stephen A Strickland, Tara L Lin

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.
Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer, Tara L Lin, Rebecca L Olin

Haematologica· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Tara L Lin, Wellington L Mendes

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.
Joshua D Mitchell, Michael Pfeiffer, John Boehmer, John Gorcsan, Shunsuke Eguchi, Nalina Dronamraju, Tara L Lin

Cardiooncology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Sponsors on Development of Clinical Research in Multiple Myeloma and AL Amyloidosis: An In-Depth Analysis.
Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Barry S Skikne, Tara Lin

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed -Mutated or -Rearranged AML.
Joshua F Zeidner, Tara L Lin, Rina Li Welkie, Emily Curran, Kristin Koenig, Rebecca L Olin

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.
Eric D Eisenmann, Ronan Swords, Ying Huang, Shelley Orwick, Daelynn Buelow, Tara L Lin

Cancer Res Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia.
Maire Okoniewski, Jesus Gonzalez Lugo, Tara L Lin

Am Soc Clin Oncol Educ Book· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.
Athalia R Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha, Tara L Lin

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are you ready for it? VEN-HMA for younger patients with AML.
Tara L Lin

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.
Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer, Tara L Lin, Robert H Collins, Rebecca L Olin

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.
John M Pagel, Megan Othus, Guillermo Garcia-Manero, Min Fang, Jerald P Radich, Tara L Lin, Selina M Luger

JCO Oncol Pract· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era.
Margaret Kasner, Angela H Fritsche, Man Chong Leong, Kendra Cameron, Carrie B Lee, Tara L Lin

JCO Oncol Pract· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
Geoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, Robert K Stuart, Roland B Walter, Tara L Lin

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma.
Aroog Khaliq, William Wesson, Emerson Logan, Carine Tabak, Muhammad Umair Mushtaq, Tara Lin

Clin Lymphoma Myeloma Leuk· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Fieke W Hoff, William G Blum, Ying Huang, Rina Li Welkie, Ronan T Swords, Tara L Lin, Robert H Collins, Rebecca L Olin

Blood Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
Mark R Litzow, Zhuoxin Sun, Ryan J Mattison, Elisabeth M Paietta, Kathryn G Roberts, Tara L Lin, Selina M Luger

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center.
Xiaosong Shi, Dinesh Pal Mudaranthakam, Jo A Wick, David Streeter, Jeffrey A Thompson, Tara L Lin

Contemp Clin Trials Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the impact of delayed study startup on accrual in cancer studies.
Isuru Ratnayake, Anh-Tuan Do, Daniel Gajewski, Sam Pepper, Oluwatobiloba Ige, Tara L Lin

Res Sq· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to 'blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives'.
Dahniel Sastow, Joshua Tatarian, Christian Salib, Tara L Lin, Douglas Tremblay

Leuk Lymphoma· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, John M Pagel, Jerald P Radich, Tara L Lin, Selina M Luger

Leukemia· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The approach of HMA plus VEN with or without BMT for all patients with AML.
Heather J Male, Tara L Lin

Hematology Am Soc Hematol Educ Program· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis